<DOC>
	<DOCNO>NCT01872065</DOCNO>
	<brief_summary>The purpose study evaluate safety , tolerability pharmacokinetics ARC-520 normal , adult volunteer .</brief_summary>
	<brief_title>Safety Tolerability Study ARC-520 Healthy Volunteers</brief_title>
	<detailed_description />
	<criteria>Key Healthy male female subject , 1855 year age Be nonsmoker Key History clinically relevant medical illness Investigator opinion may jeopardize subject safety interfere participation study , include limited hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic , allergic disease Acute sign hepatitis/other infection ( e.g. , moderate fever , jaundice , nausea , vomit , abdominal pain ) evident within 4 week screen and/or screen examination . Use drug know induce inhibit hepatic drug metabolism within 30 day prior administration study treatment . Is seropositive HIV , HBV , HCV , and/or history delta virus hepatitis . Currently use and/or history alcohol and/or drug abuse &lt; 12 month screen . Use investigational agent device within 30 day prior plan study dose current participation investigational study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>